Bacteriemia y fungemia nosocomial en adultos en un hospital terciarioestudio de un año
- Miguel Montejo 1
- J.L. Hernández 1
- A. Martín 1
- K. Aguirrebengoa 1
- J. Fernández 1
- J.R. Benito 1
- J. Oñate 1
- L. López 1
- B. Vilar 1
- P. González de Zárate 1
- J. Goikoetxea 1
- G. Moreno 1
- 1 Hospital de Cruces, Bizkaia
ISSN: 0304-4858, 2173-2302
Année de publication: 2002
Volumen: 99
Número: 4
Pages: 100-103
Type: Article
D'autres publications dans: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios
Objetivos de desarrollo sostenible
Résumé
Objetive: To determine the incidence, epidemiology and mortality rate associated with nosocomial bacteremia and fungemia in a tertiary care center. Materials and methods: Prospective study of adults patients with nosocomial bacteremia and fungemia who were admitted at Hospital de Cruces from February 2000 to February 2001. Infections were stratified by location of patient (ward versus intensive care unit), by presence or absence of neutropenia in patients, and by clinical service. Results: During the study period, 376 episodes of nosocomial bacteremia (27 episodes of fungemia), were detected. The incidence was 9,7 episodes per 1000 admissions. Gram-positive organisms accounted for 50,4% of cases, gramnegative organisms accounted for 40,7%, fungi 6,7% and 2,2% were caused by anaerobes. Bacteremia due to a single organism was found in the 92,8% of cases. The most common organisms were coagulase-negative staphylococci (18.2%), Staphylococcus aureus (14.7%), E. coli (13.7%) and enterococci (12.2%). Candida sp. were the sixth mosth common cause, accounting for 6.7%. The proportion of methicillin resistance among S. aureus isolates was 13.8%. Ampicillin resistance in E. faecalis and E. faecium were respectively 0% and 80%. The crude mortality rate was 24.5%. Death was considered attributable to bacteremia-fungemia in the 53.8% of cases. Conclusions: Those facts, may allow clinicians to better target empirical therapy for hospital-acquired cases of bacteremia.